BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34038034)

  • 21. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Crisis.
    Kolenova A; Maloney KW; Hunger SP
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):e193-5. PubMed ID: 27164534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Pluta A; Zwolińska M; Wawrzyniak E; Wierzbowska A; Skotnicki A; Jakubas B; Hołowiecki J; Nowak K; Kuliczkowski K; Mazur G; Haus O; Dmoszyńska A; Adamczyk-Cioch M; Jedrzejczak WW; Paluszewska M; Konopka L; Pałynyczko G
    Ann Hematol; 2006 Jun; 85(6):366-73. PubMed ID: 16523310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of axitinib with dasatinib improves the outcome of a chronic myeloid leukemia patient with BCR-ABL1 T315I mutation.
    Deng Q; Wang E; Wu X; Cheng Q; Liu J; Li X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 45(7):874-880. PubMed ID: 32879093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Differential diagnosis of chronic myeloid leukemia and the related disorders].
    Ashida T; Kanamaru A
    Nihon Rinsho; 2001 Dec; 59(12):2358-62. PubMed ID: 11766339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minor breakpoint cluster region (m-BCR) positive chronic myeloid leukaemia with an acute lymphoblastic leukaemia onset: a case report.
    Costello RT; Gabert J; Brunel V; Sainty D; Arnoulet C; Mozziconacci MJ; Camerlo J; Perret C; Gastaut JA; Bouabdallah R
    Br J Haematol; 1995 Oct; 91(2):428-30. PubMed ID: 8547089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The molecular biology diagnosis of neoplastic blood diseases].
    Teleheiev HD; Dybkov MV; Bozhko MV; Tretiak NM; Maliuta SS
    Tsitol Genet; 1998; 32(1):71-8. PubMed ID: 9695255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
    Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
    BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
    Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
    Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.
    Chen Z; Hu S; Wang SA; Konopleva M; Tang Z; Xu J; Li S; Toruner G; Thakral B; Medeiros LJ; Tang G
    Leuk Lymphoma; 2020 Dec; 61(12):2831-2838. PubMed ID: 32700989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.
    Giudice V; Ghelli Luserna di Rorà A; Serio B; Guariglia R; Giannini MB; Ferrari A; Simonetti G; Selleri C; Martinelli G
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
    Gong Z; Zhou T; Liu H; Tang G; Yin CC; Wang W; Medeiros LJ; Hu S
    Br J Haematol; 2020 Jun; 189(5):e207-e211. PubMed ID: 32237084
    [No Abstract]   [Full Text] [Related]  

  • 37. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia.
    Kirk JA; Radich J; Edmands S; Lee A; VanDevanter DR; Reems JA; Bryant EM
    Am J Hematol; 1996 Jul; 52(3):129-34. PubMed ID: 8756076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Wang J; Zhang Y; Zu Y; Li Z; Li M; Song Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):110-4. PubMed ID: 27014979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.